About
Morten joined Novo Seeds in 2016 as Investment Director. He serves on the Board of Hoba Therapeutics, Merozyne Therapeutics and NMD Pharma. Prior to joining Novo, Morten was Director of Corporate Development at H. Lundbeck A/S where he was involved in M&A, corporate strategy, BD&L, portfolio management and equity investments. While at Lundbeck Morten successfully led the acquisition of orphan neurology company Chelsea Therapeutics for 658 USD m and was involved in a range of other deals including the 1.8 USD Bn alliance with Otsuka Pharmaceuticals as well as equity investments and spinouts. Before Lundbeck, Morten worked as commercial manager in technology transfer to commercialize and establish new companies in biotech and medtech. Earlier in his career, Morten co-led the life science consulting practice at a boutique advisory firm in Copenhagen focusing on business development and management consulting. Morten holds an MSc in Human Biology from the University of Copenhagen.
Position in the VCSift Database
- • 3,360 investors hold the CEO role in VCSift. Morten Graugaard Døssing is one of them.
- • 666 investors are based in Copenhagen, Hovedstaden, Denmark.
Data sourced from 410,343 investor profiles. Updated July 2026.
Investment Focus
- Location
- Copenhagen, Denmark
Contact Information
Find more investors like Morten Graugaard
Search Investors